Quick Answer
Altimmune, Inc. reported Stockholders Equity of $224.89 million for fiscal year 2025.
Altimmune, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $224.89M | +82.1% |
| 2024 | $123.51M | -36.4% |
| 2023 | $194.10M | +4.8% |
| 2022 | $185.29M | -7.0% |
| 2021 | $199.13M | -11.8% |
| 2020 | $225.88M | +396.2% |
| 2019 | $45.52M | -5.8% |
| 2018 | $48.31M | +22.6% |
| 2017 | $39.40M | +22.3% |
| 2016 | $32.21M | -25.3% |
| 2015 | $43.13M | +136.0% |
| 2014 | $18.27M | +149.1% |
| 2013 | $7.34M | -37.2% |
| 2012 | $11.67M | -26.4% |
| 2011 | $15.85M | +29.8% |
| 2010 | $12.21M | +287.3% |
| 2009 | $3.15M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $185.60M | +39.2% | +15.0% |
| June 30, 2025 | $161.37M | +5.8% | +13.5% |
| March 31, 2025 | $142.16M | -17.8% | +15.1% |
| December 31, 2024 | $123.51M | -36.4% | -7.4% |
| September 30, 2024 | $133.38M | -11.3% | -12.6% |
| June 30, 2024 | $152.53M | -9.1% | -11.8% |
| March 31, 2024 | $172.94M | +3.1% | -10.9% |
| December 31, 2023 | $194.10M | +4.8% | +29.1% |
- Altimmune, Inc. showed an increase of +82.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2009–2025 period, Altimmune, Inc.’s stockholders equity has grown by 7034.0% (from $3.15 million to $224.89 million).
- The most recent figure is from Altimmune, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: